Day: December 30, 2021

Key Points:Meeting held with the US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) to address potency assay and chemistry, manufacturing and controls (CMC) items identified in the complete response letter (CRL) for remestemcel-L in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children OTAT indicated that Mesoblast’s approach to address the outstanding CMC items is reasonable OTAT indicated that the in vitro immunomodulatory activity Mesoblast intends to measure for potency is a reasonable critical quality attribute (CQA) for the product, and the relevance of this activity to clinical outcomes should be established Mesoblast has now generated substantial new data that it believes establish the relevance of the proposed in vitro immunomodulatory activity of remestemcel-L...

VANCOUVER, British Columbia, Dec. 30, 2021 (GLOBE NEWSWIRE) — NorthWest Copper (“NorthWest” or the “Company”) (TSX-V:NWST, OTCQX:NWXCC) announces that it has granted 3,575,000 Stock Options to directors, certain employees and consultants, and 1,175,000 Restricted Share Units (“RSUs”) to certain employees and consultants pursuant to its Stock Option and RSU Plans. The Stock Options have an exercise price of $0.80 and have a range of vesting periods over three years and expire after five years. The RSUs are payable in common shares of the Company on exercise, have a range of vesting periods over three years and must be redeemed within 30 days of December 29, 2024, or they expire. About NorthWest Copper: NorthWest is a new copper-gold explorer and developer with an exciting pipeline of projects in British Columbia. With a robust portfolio...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (All figures in Canadian dollars unless otherwise stated) TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd (TSXV: QGR, OTC: QGLDF, FRA: QX9G) (“Q-Gold” or the “Company”) is pleased to announce it is initiating a non-brokered flow-through financing (the “Offering”). The Offering will consist of up to of 9,090,910 flow-through units (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) priced at $0.11 per flow-through unit (the “Offering Price”) for gross proceeds of up to $1,000,000. Each flow-through unit will consist of one flow-through common share of the Company and one-half non-flow-through share purchase warrant. Each whole warrant will entitle the holder to acquire one common share of the Company...

TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Honey Badger Silver Inc. (TSX-V: TUF) (“Honey Badger Silver” or the “Company”) announces that the Board of Directors has approved the grant of stock options to directors, officers, employees and consultants of the Company for the purchase of up to 4,809,800 shares in the Company exercisable at a price of $0.075 for a period of five years from the date of grant. The grant is pursuant and subject to the terms and conditions of the Company’s existing stock option plan and is subject to the approval of the TSX Venture Exchange and all regulatory requirements. ON BEHALF OF THE BOARD Chad WilliamsExecutive Chairman and Director About Honey Badger Silver Inc. Honey Badger Silver is a Canadian Silver company based in Toronto, Ontario focused on the acquisition, development and integration of accretive...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Jourdan Resources Inc. (TSX-V: JOR) (“Jourdan” or the “Company”) announces that it intends to complete a best efforts non-brokered private placement flow-through financing of up to 40,000,000 units (each, a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to $2,000,000 (the “Offering”). Each Unit will be issued on a “flow-through basis” and will consist of one common share of the Company and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one additional common share of the Company at an exercise price of $0.08 for a period of 24 months from issuance. Closing of the Offering is expected to occur on or about...

CHARLOTTE, N.C., Dec. 30, 2021 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY) announced today that the Company will participate virtually in the 40th Annual J.P. Morgan Healthcare Conference. Don Casey, Chief Executive Officer, is scheduled to present on Wednesday, January 12, 2022 at 11:15 am ET. A live audio webcast and presentation materials will be available through the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. A replay of the webcast will be available for 30 days following the presentation. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 134-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and...

BOULDER, Colo., Dec. 30, 2021 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. SomaLogic management is scheduled to present on Tuesday, January 11, 2022, at 11:15 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://investors.somalogic.com. About SomaLogicSomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users,...

SUNNYVALE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Silk Road Medical’s management is scheduled to present on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.silkroadmed.com/.  About Silk Road MedicalSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery...